Access cutting-edge brain cancer treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access brain cancer specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related brain cancer treatment provided free
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a
Sponsor: Nationwide Children's Hospital
Check if you qualify for this brain cancer clinical trial in Washington Dc, DC
If you're searching for brain cancer treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced brain cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.